SCHEMBL38665341

SCHEMBL38665341

CC[C@@H]1CN(C(=O)OC(C)(C)C)CCN1c1cccc(Br)c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 3/20 0.43
GPR119 Q8TDV5 4/20 0.43
PARP1 P09874 1/20 0.41
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
HSD17B10 Q99714 1/20 0.40
BACE1 P56817 1/20 0.39
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
SMARCA2 P51531 1/20 0.39
SMARCA4 P51532 1/20 0.39
PBRM1 Q86U86 1/20 0.39
ADAMTS5 Q9UNA0 1/20 0.39
MGLL Q99685 2/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
THRB P10828 1/20 0.39
KAT7 O95251 1/20 0.39
DPP4 P27487 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12336485 0.87 ALDH1A1 (0.46) USP30GPR119PARP1ALDH1A1MAPT
SCHEMBL31484639 0.86 GPR119 (0.52) USP30GPR119PARP1SMARCA2SMARCA4
SCHEMBL30775709 0.85 LMNA (0.50) USP30GPR119ALDH1A1MAPTSMARCA2
SCHEMBL23784833 0.85 LMNA (0.50) USP30GPR119ALDH1A1MAPTSMARCA2
SCHEMBL23784831 0.85 LMNA (0.50) USP30GPR119ALDH1A1MAPTSMARCA2
SCHEMBL23784884 0.85 LMNA (0.50) USP30GPR119ALDH1A1MAPTSMARCA2
SCHEMBL38664491 0.82 GPR119 (0.42) USP30GPR119PARP1SMARCA2SMARCA4
SCHEMBL38663929 0.82 GPR119 (0.42) USP30GPR119PARP1SMARCA2SMARCA4
SCHEMBL19690205 0.82 HDAC6 (0.51) USP30GPR119MAPTBACE1NR1H2
SCHEMBL14932381 0.80 GPR119 (0.57) GPR119PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 WO disclosed